1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Strides Pharma Science Limited

Strides Pharma Science Limited

STAR.NS
Strides Pharma Science LimitedIN flagNational Stock Exchange of India
1,125.40
INR
+3.80
- -
103.73BMarket Cap
Strides Pharma Science Limited
STAR.NS
(National Stock Exchange of India)

Recent

price

1,125.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
325.42
361.64
431.33
152.09
189.94
333.13
297.24
312.53
235.44
296.67
362.81
336.73
400.49
409.88
496.18
- -
502.97
Revenue per Share
27.36
26.11
38.55
144.3
141.85
13.14
44.73
74.26
36.25
4.06
29.96
-51.28
-22.49
-7.76
390.55
- -
37.1
Basic EPS, GAAP
-10.34
33.54
37.42
22.89
14
-35.83
-44.11
-24.09
6.71
22.87
53.73
-28.73
4.93
77.04
74.38
- -
- -
Free Cash Flow per Basic Share
0.12
1.62
1.73
2
110.01
2.98
4.84
4.95
2
17.18
2
2.5
- -
1.49
2.5
- -
- -
Dividend per Share
22.29
64.3
86.58
10.03
-51.55
-5.67
34.45
25.13
52.54
36.18
64.13
10.26
-12.21
-21.16
59.89
- -
- -
Book Value per Share
-26.96
-18.22
-185.97
-17.7
147.47
54.41
23.69
9.15
-9.45
180.88
191.38
141.78
121.67
111.56
159.97
- -
- -
Tangible Book Value per Share
40
47
58
59
60
83
89
89
90
90
90
90
90
91
92
- -
92
Basic Weighted Avg Shares
13,048
16,958
25,116
8,919
11,315
27,512
26,564
27,965
21,083
26,567
32,512
30,221
36,077
37,300
45,653
48,587
46,307
Sales/Revenue/Turnover
12.36
14
16.58
14.28
15.83
10.47
16.19
8.88
6.56
13.79
12.96
-8
3.96
8.61
13.37
14.88
13.74
Operating Margin (%)
493
639
1,043
1,095
640
1,520
1,987
1,939
1,718
1,878
2,063
2,330
2,433
2,207
1,923
2,024
1,946
Depreciation Expense
1,097
1,224
2,245
8,462
8,450
1,085
3,997
6,645
3,246
364
2,684
-4,602
-2,026
-706
35,935
5,562
3,416
Net Income, GAAP
15.32
24.25
14.15
1.54
35.83
26.43
18.48
7.11
- -
20.71
11.49
- -
- -
- -
15.92
14.09
17.49
Effective Tax Rate (%)
8.41
7.22
8.94
94.88
74.68
3.94
15.05
23.76
15.4
1.37
8.26
-15.23
-5.62
-1.89
78.71
11.45
7.38
Profit Margin (%)
2,661
10,368
-11,665
-3,864
4,429
16,236
6,880
5,867
3,889
-1,702
815
-473
2,557
932
5,102
7,178
- -
Working Capital
14,569
20,098
10,543
7,311
2,548
26,285
16,377
15,591
18,149
8,577
10,928
10,221
13,435
7,431
6,227
6,042
- -
LT Debt
10,896
15,553
14,169
20,981
11,697
27,081
28,874
26,183
28,017
25,947
28,140
23,833
21,729
20,717
25,865
31,493
- -
Total Equity
6.15
5.88
9.38
3.24
3.97
5.05
5.74
4.18
- -
5.32
7.45
- -
- -
- -
11.27
13.15
- -
Return on Invested Capital (%)
5.82
9.44
12.77
37.34
74.89
11.59
13.36
24.23
- -
2.05
14.21
- -
- -
- -
160.42
31.73
290.64
Return on Capital (%)
122.83
62.65
55.72
300.65
- -
- -
- -
249.47
93.37
9.16
59.75
-138.05
- -
- -
- -
172.93
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
12,569
- -
LT Borrowings
- -
5,712
- -
LT Finance Leases
- -
515
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
92
- -
Market Capitalization
60,641
61,573
82,829

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
31,017
- -
Cash, Cash Equivalents & STI
- -
1,986
- -
Accounts Receivable, Net
- -
12,029
- -
Inventories
- -
12,776
- -
Total Current Liabilities
- -
25,915
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
12,569
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.32%
3.56%
21.76%
Free Cash Flow
144.42%
241.61%
2.65%
Net Income, GAAP
-483.38%
-1,133.22%
-84.52%
Sales/Revenue/Turnover
7.01%
8.91%
6.43%
Total Cash Common Dividend
- -
- -
60.35%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,300
9,994
10,058
9,239
37,300
2025
10,543
11,669
11,537
11,904
45,653
2026
11,197
11,946
13,235
- -
48,587

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.79
-14.54
5.43
- -
-7.76
2025
364.65
7.81
9.56
8.92
390.55
2026
10.81
21.93
13.77
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.49
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
- -
Similar Companies
Medical Developments International Limited (MVP.AX)
Medical Marijuana, Inc. (MJNA)
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ)
Levitee Labs Inc. (LVTTF)
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ)
Medicamen Biotech Limited (MEDICAMEQ.BO)
Business
Strides Pharma Science Limited, headquartered in Bengaluru, India and founded in 1990, develops and manufactures a broad portfolio of pharmaceutical products including niche generic formulations, soft gelatin capsules, hard gelatin capsules, tablets, ointments, dry and wet injectables, over-the-counter drugs and nutraceuticals; it specializes in IP-led finished dosage forms across therapeutic categories such as anti-emetics, cardiovascular, dermatology, anti-infectives and opioids for regulated markets including the United States, Europe, Australia and emerging markets. The company operates manufacturing facilities across four continents with eight sites in India, facilities in the United States, Italy and Kenya, and maintains marketing presence in over 100 countries through partnerships with generic firms for retail and hospital supply of injectables and softgels. Subsidiaries include Strides Pharma Inc. in the USA, Beltapharm S.r.l. in Italy and Universal Corporation Limited in Kenya. In April 2025, Strides acquired four approved Abbreviated New Drug Applications (ANDAs) from Nostrum Laboratories for the US market valued at approximately USD 57 million for USD 2.075 million, planning launches of two commercial products within 12 months; recent financials reflect Q2 FY2026 revenue growth of 4.6% year-over-year, EBITDA up 25.4% and operational PAT up 84%, targeting USD 400 million US revenue by FY2028.